Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab Intense Dosing with CHOP-21 in DLBCL
NCT01539174Phase 2Withdrawn
- Sponsor
- Fox Chase Cancer Center
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in diffuse large B-cell lymphoma (DLBCL), sponsored by Fox Chase Cancer Center. Status: withdrawn.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT01539174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01539174.